Detalhe da pesquisa
1.
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial.
Wien Klin Wochenschr
; 133(17-18): 931-941, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34378087